Sanofi's vaccine division, Sanofi Pasteur, is building a state-of-the-art plant in India as part of a 2015 goal to achieve 40% of sales from emerging markets. The facility, touted as the largest in Asia, will be fully operational in October 2012. Sanofi invested $300 million for capacity expansion after buying India's Shantha Biotechnics in 2009, said CEO Chris Viehbacher.

Related Summaries